On 14 October 2016, orphan designation (EU/3/16/1760) was granted by the European Commission to Wainwright Associates Ltd, United Kingdom, for radio-iodinated (131I) anti-CD45 murine monoclonal antibody (also known as Iomab-B) for treatment in haematopoietic stem cell transplantation.
Radio-iodinated (131I) anti-CD45 murine monoclonal antibody
Treatment in haematopoietic stem cell transplantation
|Orphan designation status||
|EU designation number||
|Date of designation||
|September 2022||The sponsorship was transferred to Immedica Pharma AB, Sweden.|
|October 2021||Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.|
|April 2021||The sponsorship was transferred to Voisin Consulting S.A.R.L., France.|
|April 2019||The sponsorship was transferred to YES Pharmaceuticals Development Services GmbH, Germany.|
|November 2016||Wainwright Associates Ltd changed name to PharmaLex UK Services Limited.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: